{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:49:16Z","timestamp":1785192556627,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jcf.2022.02.003","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T16:20:19Z","timestamp":1645201219000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u2265\u00a06 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant"],"prefix":"10.1016","volume":"21","author":[{"given":"Gregory S.","family":"Sawicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chilvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-9777","authenticated-orcid":false,"given":"Clare","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-401X","authenticated-orcid":false,"given":"Neil","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegarde","family":"Paz-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy L.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcf.2022.02.003_bib0001","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.05.005","article-title":"Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening","volume":"155","author":"Stick","year":"2009","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2022.02.003_bib0002","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jpeds.2003.09.026","article-title":"Structural airway abnormalities in infants and young children with cystic fibrosis","volume":"144","author":"Long","year":"2004","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.jcf.2022.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1164\/rccm.200412-1665OC","article-title":"High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis","volume":"172","author":"Mart\u00ednez","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2022.02.003_bib0004","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201610-2158OC","article-title":"Progression of lung disease in preschool patients with cystic fibrosis","volume":"195","author":"Stanojevic","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.02.003_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"issue":"10059","key":"10.1016\/j.jcf.2022.02.003_bib0006","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcf.2022.02.003_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ppul.24215","article-title":"Patients with cystic fibrosis having a residual function mutation: data from the Italian registry","volume":"54","author":"Salvatore","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2022.02.003_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2022.02.003_bib0009","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.130.5.1441","article-title":"CFTR genotype as a predictor of prognosis in cystic fibrosis","volume":"130","author":"McKone","year":"2006","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jcf.2022.02.003_bib0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200403-404OC","article-title":"Late diagnosis defines a unique population of long-term survivors of cystic fibrosis","volume":"171","author":"Rodman","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"10.1016\/j.jcf.2022.02.003_bib0011","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-Tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.jcf.2022.02.003_bib0012","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jcf.2022.02.003_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2022.02.003_bib0014","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.02.003_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jcf.2022.02.003_bib0016","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.jcf.2022.02.003_bib0017","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.jcf.2022.02.003_bib0018","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.jcf.2022.02.003_bib0019","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2022.02.003_bib0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","article-title":"A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11years with cystic fibrosis","volume":"18","author":"Walker","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2022.02.003_bib0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2022.02.003_bib0022","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.02.003_bib0023","unstructured":"Vertex Pharmaceuticals Incorporated. Kalydeco (ivacaftior) [package insert]. Boston, MA. 2020."},{"issue":"6","key":"10.1016\/j.jcf.2022.02.003_bib0024","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/thoraxjnl-2012-202345","article-title":"Multiple-breath washout measurements can be significantly shortened in children","volume":"68","author":"Yammine","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.02.003_bib0025","unstructured":"Cystic Fibrosis Foundation. 2019 Patient Registry annual report. https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2019-Patient-Registry-Annual-Data-Report.pdf. Accessed September 10, 2021."},{"issue":"1","key":"10.1016\/j.jcf.2022.02.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02686-2020","article-title":"Longitudinal course of clinical lung clearance index in children with cystic fibrosis","volume":"58","author":"Frauchiger","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jcf.2022.02.003_bib0027","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2022.02.003_bib0028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.02.003_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2022.02.003_bib0030","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2022.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2022.02.003_bib0032","doi-asserted-by":"crossref","first-page":"e000998","DOI":"10.1136\/bmjresp-2021-000998","article-title":"Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies","volume":"8","author":"Bresnick","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"10.1016\/j.jcf.2022.02.003_bib0033","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in 1 Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"2021","journal-title":"J Appl Physiol"},{"issue":"21","key":"10.1016\/j.jcf.2022.02.003_bib0034","first-page":"01374","article-title":"Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials","author":"Robinson","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:45:46Z","timestamp":1761601546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1569199322000339"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.02.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u2265\u00a06 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}